Skip to main
BSX

Boston Scientific (BSX) Stock Forecast & Price Target

Boston Scientific (BSX) Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 45%
Buy 55%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Boston Scientific is projected to experience robust growth driven by anticipated increases in procedure volumes in the atrial fibrillation (AF) market, with estimates suggesting a 20-30% rise in left atrial appendage closure (LAAC) volumes due to expanded indications and broader adoption. The global AFib market is expected to grow from $9 billion to $15 billion by 2028, representing a significant compound annual growth rate (CAGR), alongside a projected 15% CAGR for the total electrophysiology (EP) market. With positive trial results and innovations in catheter technologies, Boston Scientific is well-positioned to capture substantial market share, as evidenced by survey respondents projecting approximately 18% incremental increases in procedure volumes following successful clinical trial outcomes.

Bears say

The financial outlook for Boston Scientific is negatively impacted by several key factors, including a projected decline in the company's market share for RF and cryoablation products, which are expected to fall significantly, indicating a loss of competitiveness in these segments. Additionally, concerns over slower-than-anticipated adoption of the company's portfolio, particularly related to recent acquisitions, alongside limited operating leverage and increasing debt levels, suggest an unfavorable financial trajectory. Furthermore, the company faces heightened risks from competitive product launches, potential delays in new product approvals, and pricing pressures in its CRM and DES portfolios, which are crucial to its overall revenue.

Boston Scientific (BSX) has been analyzed by 20 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 55% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Boston Scientific and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Boston Scientific (BSX) Forecast

Analysts have given Boston Scientific (BSX) a Buy based on their latest research and market trends.

According to 20 analysts, Boston Scientific (BSX) has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $100.95, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $100.95, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Boston Scientific (BSX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.